Canada markets closed

Biomerica, Inc. (BMRA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.2900+0.1500 (+13.16%)
At close: 03:59PM EST
1.2900 0.00 (0.00%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close1.1400
Open1.1600
Bid1.2900 x 4000
Ask1.3000 x 2200
Day's Range1.1500 - 1.3500
52 Week Range0.7000 - 2.7800
Volume206,934
Avg. Volume1,255,721
Market Cap21.7M
Beta (5Y Monthly)-1.09
PE Ratio (TTM)N/A
EPS (TTM)-0.3800
Earnings DateApr 12, 2024 - Apr 16, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board

    Mr. Huff was the Former CEO of LabCorp Diagnostics and joins with significant executive experience and a proven track record in medical diagnostics and healthcareIRVINE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, proudly announces the appointment of Gary Huff to its Strategic Advisory Board (SAB). Mr. Huff, former CEO of Diagnostics at Laboratory Corporation of America Holdings, “

  • GlobeNewswire

    Diagnostics Industry Leader Jack Kenny Appointed as Chairman of the Board at Biomerica

    Mr. Kenny has significant executive experience and a proven track record in medical diagnostics and healthcare Mr. Kenny most recently served as CEO of Meridian Bioscience where he successfully built and ultimately managed the sale of the company for $1.53 billion IRVINE, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, today announced the appointment of Jack Kenny, former CEO and board

  • GlobeNewswire

    Biomerica Reports Second Quarter 2024 Financial Results

    Revenues excluding Covid test sales increased 10.3% for the second fiscal quarter of 2024 vs the second fiscal quarter of 2023.Loss per shares narrows to $0.09 per share from $0.12 per share reflecting disciplined operating expense management.Company Received US FDA 510(k) Clearance for Its Hp Detect™ ELISA Test Product Designed to Detect the Presence of the H. pylori Bacteria That infects approximately 35% of the U.S. Population. IRVINE, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc.